All articles by Alejandro Gonzalez

  1. Stealth’s Phase III elamipretide in mitochondrial myopathy has experts wary while FDA approval debated

    Stealth BioTherapeutics’ elamipretide in primary mitochondrial myopathy (PMM) has experts reserved on Phase III achieving statistical success in its walk…
    Read More…

    17 Jun
  2. Amarin’s Vascepa, AstraZeneca’s Epanova theoretical cardiovascular risk reduction class effect possibly stifled

    Although Amarin’s Vascepa (icosapent ethyl) is likely to lock in US Food and Drug Administration approval and swift uptake in…
    Read More…

    17 Jun
  3. Positive results reported for Eli Lilly’s ultra-rapid insulin

    During the American Diabetes Association’s (ADA’s) 79th Scientific Sessions held in San Francisco, California, US, delegates were able to hear…
    Read More…

    17 Jun
  4. Signs of advancement in metastatic hormone-naive prostate cancer treatment

    Among this year’s biggest developments in prostate cancer was the release of data in patients with metastatic hormone-naive prostate cancer…
    Read More…

    17 Jun
  5. Erleada looks to advance treatment of metastatic hormone-sensitive prostate cancer paradigm

    During this year’s American Society of Clinical Oncology (ASCO 2019) meeting in Chicago, several prostate cancer trials of second-generation hormonal…
    Read More…

    13 Jun
  6. Eli Lilly is likely to establish Emgality in the preventative migraine market

    The migraine market has many unmet needs. In the preventative treatment of migraines, the market is dominated by non-specific drugs…
    Read More…

    13 Jun
  7. Characterising Eastern China’s pharmaceutical manufacturing market: Shandong and Jiangsu

    The following article is the second of two articles covering Eastern China, specifically Shandong and Jiangsu (eastern provinces north of the…
    Read More…

    13 Jun
  8. Stroke: a growing burden across eight major markets to 2027

    A stroke occurs when blood supply to the brain is interrupted by a clot or when a blood vessel bursts….
    Read More…

    12 Jun
  9. Fine-tuning checkpoint inhibitor use in triple-negative breast cancer

    This year’s American Society of Clinical Oncology (ASCO 2019) meeting in Chicago was a testament to the widespread use of…
    Read More…

    12 Jun
  10. The microbiome in IBD: multiomics analysis may help clarify an elusive mechanism of action

    On 29 May, a treasure trove of data from the US National Institutes of Health’s (NIH) Human Microbiome Project (HMP)…
    Read More…

    11 Jun
Close
Close
Close

Go Top